Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Frontage Holdings's share price for the quarter that ended in Dec. 2025 was HK$1. Frontage Holdings's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 2,028 Mil. Therefore, Frontage Holdings's market cap for the quarter that ended in Dec. 2025 was HK$2,028 Mil.
Frontage Holdings's quarterly market cap
declined
from Dec. 2024 (HK$3,663 Mil) to Jun. 2025 (HK$2,170 Mil) and
declined
from Jun. 2025 (HK$2,170 Mil) to Dec. 2025 (HK$2,028 Mil).
Frontage Holdings's annual market cap
declined
from Dec. 2023 (HK$4,749 Mil) to Dec. 2024 (HK$3,663 Mil) and
declined
from Dec. 2024 (HK$3,663 Mil) to Dec. 2025 (HK$2,028 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Frontage Holdings's Enterprise Value for Today is HK$3,259 Mil.
Frontage Holdings (HKSE:01521) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Frontage Holdings Market Cap Related Terms
Frontage Holdings Market Cap Historical Data
* Premium members only.
The historical data trend for Frontage Holdings's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01521 vs VRTX, REGN, RVMD: Market Cap Comparison
For the Biotechnology subindustry, Frontage Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Frontage Holdings Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Frontage Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Frontage Holdings's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Frontage Holdings's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Frontage Holdings (HKSE:01521) has a Market Cap of HK$2,636 Mil as of Aug. 07, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Frontage Holdings and its competitors. According to the industry distribution chart, Frontage Holdings ranks #498 out of 1423 companies in the Biotechnology industry, placing it in the top 35%.
Is Frontage Holdings' Market Cap too high?
Frontage Holdings' current Market Cap is HK$2,636 Mil. Based on the distribution chart, Frontage Holdings ranks #498 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Frontage Holdings has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Frontage Holdings' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Frontage Holdings ranks #498 out of 1423 companies for Market Cap. This puts Frontage Holdings in the upper half of its industry. The industry median Market Cap is 116.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 116.70, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Frontage Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 116.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Frontage Holdings's current Market Cap is HK$2,636 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Frontage Holdings stock overvalued right now?
Based on GuruFocus' analysis, Frontage Holdings (HKSE:01521) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$1.55, compared to a current price of HK$1.30 — trading 16.1% below its estimated fair value. The current Market Cap is HK$2,636 Mil. Frontage Holdings' overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Frontage Holdings (HKSE:01521), the current Market Cap is HK$2,636 Mil as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Frontage Holdings (HKSE:01521) Overvalued in 2026?
Based on GuruFocus' analysis, Frontage Holdings stock appears to be undervalued.
The current stock price of HK$1.30 is trading 16.1% below its estimated GF Value™ of HK$1.55.
GuruFocus considers Frontage Holdings to be Modestly Undervalued.
Key valuation signals for HKSE:01521:
Market Cap: HK$2,636 Mil
GF Value™: HK$1.55 vs. price of HK$1.30 (16.1% below fair value)
No single metric tells the full story. See the HKSE:01521 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Frontage Holdings Corp provides laboratory and related services to pharmaceutical and agrochemical companies. Its segments include North America and Europe segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the USA, Canada and Europe; and PRC segment, including drug discovery, drug development, pharmaceutical product development and laboratory testing in the PRC. It derives majority of the revenue from North America and Europe segment. Geographically majority of the revenue is derived from USA and Canada.
88GF Score
Get the complete analysis for HKSE:01521
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01521 has been successfully added to your 
